OKYO Pharma
A clinical-stage biopharmaceutical company developing ocular therapies for the treatment of inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP).
OKYO’s flagship drug candidate OK-101 is a lipidated chemerin-peptide, designed to target a key ocular receptor controlling inflammation and ocular pain. The drug, developed by a unique proprietary membrane anchored technology, is designed to increase agonist potency and ocular residence time.
Latest OKYO Pharma News & Features
22 March 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze